Terms: = Prostate cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Diagnosis
13 results:
1. Molecular Landscape of LncRNAs in prostate cancer: A focus on pathways and therapeutic targets for intervention.
Mirzaei S; Paskeh MDA; Okina E; Gholami MH; Hushmandi K; Hashemi M; Kalu A; Zarrabi A; Nabavi N; Rabiee N; Sharifi E; Karimi-Maleh H; Ashrafizadeh M; Kumar AP; Wang Y
J Exp Clin Cancer Res; 2022 Jul; 41(1):214. PubMed ID: 35773731
[TBL] [Abstract] [Full Text] [Related]
2. Nucleic acids therapeutics using PolyPurine Reverse Hoogsteen hairpins.
Noé V; Aubets E; Félix AJ; Ciudad CJ
Biochem Pharmacol; 2021 Jul; 189():114371. PubMed ID: 33338475
[TBL] [Abstract] [Full Text] [Related]
3. Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis.
Yuan Z; Fernandez D; Dhillon J; Abraham-Miranda J; Awasthi S; Kim Y; Zhang J; Jain R; Serna A; Pow-Sang JM; Poch M; Li R; Manley B; Fink A; Naghavi A; Torres-Roca JF; Grass GD; Kim S; Latifi K; Hunt D; Johnstone PAS; Yamoah K
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):140-149. PubMed ID: 32651467
[TBL] [Abstract] [Full Text] [Related]
4. Mismatch repair deficiency in metastatic prostate cancer: Response to pd-1 blockade and standard therapies.
Graham LS; Montgomery B; Cheng HH; Yu EY; Nelson PS; Pritchard C; Erickson S; Alva A; Schweizer MT
PLoS One; 2020; 15(5):e0233260. PubMed ID: 32453797
[TBL] [Abstract] [Full Text] [Related]
5. Predominance of M2 macrophages in gliomas leads to the suppression of local and systemic immunity.
Vidyarthi A; Agnihotri T; Khan N; Singh S; Tewari MK; Radotra BD; Chatterjee D; Agrewala JN
Cancer Immunol Immunother; 2019 Dec; 68(12):1995-2004. PubMed ID: 31690954
[TBL] [Abstract] [Full Text] [Related]
6. [Molecular tumor board prostate cancer].
Seitz AK; Heck MM; Kamer MW; Grüllich C
Urologe A; 2019 Jul; 58(7):752-759. PubMed ID: 31049637
[TBL] [Abstract] [Full Text] [Related]
7. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab.
Zhang HC; Luo W; Wang Y
J Immunother Cancer; 2019 Feb; 7(1):47. PubMed ID: 30777137
[TBL] [Abstract] [Full Text] [Related]
8. Analysis of the Prevalence of Microsatellite Instability in prostate cancer and Response to Immune Checkpoint Blockade.
Abida W; Cheng ML; Armenia J; Middha S; Autio KA; Vargas HA; Rathkopf D; Morris MJ; Danila DC; Slovin SF; Carbone E; Barnett ES; Hullings M; Hechtman JF; Zehir A; Shia J; Jonsson P; Stadler ZK; Srinivasan P; Laudone VP; Reuter V; Wolchok JD; Socci ND; Taylor BS; Berger MF; Kantoff PW; Sawyers CL; Schultz N; Solit DB; Gopalan A; Scher HI
JAMA Oncol; 2019 Apr; 5(4):471-478. PubMed ID: 30589920
[TBL] [Abstract] [Full Text] [Related]
9. New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions.
Schiano C; Soricelli A; De Nigris F; Napoli C
Expert Rev Clin Immunol; 2019 Mar; 15(3):289-301. PubMed ID: 30570412
[TBL] [Abstract] [Full Text] [Related]
10. Clinical Features and Therapeutic Outcomes in Men with Advanced prostate cancer and DNA Mismatch Repair Gene Mutations.
Antonarakis ES; Shaukat F; Isaacsson Velho P; Kaur H; Shenderov E; Pardoll DM; Lotan TL
Eur Urol; 2019 Mar; 75(3):378-382. PubMed ID: 30337059
[TBL] [Abstract] [Full Text] [Related]
11. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies.
Sfanos KS; Markowski MC; Peiffer LB; Ernst SE; White JR; Pienta KJ; Antonarakis ES; Ross AE
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):539-548. PubMed ID: 29988102
[TBL] [Abstract] [Full Text] [Related]
12. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.
Majzner RG; Simon JS; Grosso JF; Martinez D; Pawel BR; Santi M; Merchant MS; Geoerger B; Hezam I; Marty V; Vielh P; Daugaard M; Sorensen PH; Mackall CL; Maris JM
Cancer; 2017 Oct; 123(19):3807-3815. PubMed ID: 28608950
[TBL] [Abstract] [Full Text] [Related]
13. Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or pd-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse.
Nardone V; Botta C; Caraglia M; Martino EC; Ambrosio MR; Carfagno T; Tini P; Semeraro L; Misso G; Grimaldi A; Boccellino M; Facchini G; Berretta M; Vischi G; Rocca BJ; Barone A; Tassone P; Tagliaferri P; Del Vecchio MT; Pirtoli L; Correale P
Cancer Biol Ther; 2016 Nov; 17(11):1213-1220. PubMed ID: 27791459
[TBL] [Abstract] [Full Text] [Related]
